ArticlePatient preference and adherence2025
Disease Impact and Perception of Biologics in Adults with Type 2 Inflammation Respiratory Disease: International Survey Results.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Global Patient Perspective on Uncontrolled Moderate-to-Severe Asthma: Reducing Delays in Diagnosis and Treatment.Advances in therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: There is a growing interest in developing approaches that reduce the impact of Type 2 inflammatory conditions, such as asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), on well-being. The aim of this international survey was to understand the impact of asthma and CRSwNP on people living with these conditions and to seek insight into the perception of biologics, which are often used to treat them. Patients and Methods: A cross-sectional survey was conducted anonymously online from February to May 2024. International participants were recruited through social media and by Survey Monkey. Individuals aged ≥18 years diagnosed by a medical professional with asthma and/or CRSwNP who lived in the US, Canada, UK, Germany, Italy, France, or Spain were eligible to participate. Results: Of the 1566 survey participants (56.7% asthma, 24.8% CRSwNP, 18.5% both), 52.5% were female, and 65.3% were ages 25-54 years. Approximately two-thirds (64%) reported thinking once/day or at least once/week about managing their condition. Nearly half (44%) find it difficult to manage their disease. Of those currently using a biologic (14%), only 37% inject it themselves and feel confident doing so, and 42% felt it was a repeating reminder of their chronic condition. The top reason for stopping biologic treatment was that the injection/device was too difficult. The possibility of a lower frequency injection increased the likelihood participants would consider a biologic. Conclusion: The study further raises awareness of the personal burden from asthma and CRSwNP and their associated treatments in different countries. Beyond the goal of achieving clinical disease control for these diseases, a holistic approach to care delivery should include culturally appropriate emotional health support to improve overall well-being. Access to biologics administered with less frequency may alleviate some of the burden of self-injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.